Clinical Effect of Imatinib, Nilotinib, and Dasatinib on Chronic Myeloid Leukemia in Chronic Phase

Abstract

The study was conducted to explore the effect of imatinib, nilotinib, and dasatinib in the treatment of chronic myeloid leukemia (CML) patients. Around 66 patients with CML in chronic phase were selected, subsequently the patients were subdivided into 3 groups with 22 patients in each group: Group A were treated with imatinib; Group B were treated with nilotinib; and Group C were treated with dasatinib. The study showed that, at 18 months of treatment, compared with group A, the molecular biology remission rates of group B and group C were significantly higher, p<0.05; at 6 months and 18 months of treatment, compared with group A, the complete cytogenetic remission rates of group B and group C were significantly higher, p<0.05; and compared with group A, the incidences of vomiting, headache and edema in groups B and C were significantly lower, p<0.05. However, no significant different p>0.05 were observed in the complete hematologic remission rates, and the incidences of neutropenia and thrombocytopenia among the three groups. In summary, nilotinib and dasatinib are effective in the treatment of patients with CML in the chronic phase, which is significantly better than imatinib treatment.